Norman Z.
Managing Director at Boxer Capital
San Francisco Bay Area
Overview
Work Experience
Board of Directors
2020 - Current
Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway.
Raised $70,000,000.00 from Boxer Capital, Canaan Partners and RA Capital Management.
Managing Director
2016
Boxer Capital invents and invests in biotechnology companies that aim to drastically improve medicine. * Sourced and originated new public and private investment opportunities. * Led the assessment of management teams, science, clinical development plans, regulatory approval feasibility, commercial opportunities, IP, competitive landscape and financial plans to determine the overall potential of investment opportunities. * Prepared and presented investment material and supporting documentations associated with transactions. * Participated in investment decision making, deal structuring and negotiations. * Oversaw general strategy, finance and operation of portfolio companies.
Board of Directors (Observer)
2020 - 2021
Executive Council
2014 - 2017
International Collaboration Committee Promotion & Fundraising Committee
Industry advisor SPARK
2013 - 2017
Mentor, UCSF Innovation, Technology & Alliances
2015 - 2016
Genentech
2012 - 2016
* Lead development scientist in projects across Genentech portfolio (oncology, immunology, infectious disease, and ophthalmology) * Drove strategic decisions and allocated resources in accordance with corporate priorities to advance drug candidates from discovery stage through Investigational New Drug (IND) to FIH and POC clinical trial * Formulated and implemented robust, patient-focused preclinical and clinical development plans * Global project lead for CQA (critical quality attribute)-SC PK initiatives
Roche Molecular Systems, Inc., a molecular diagnostics company, develops and commercializes diagnostic and blood screening tests based on
Duke Clinical Research Institute
2012 - 2012
Clinical Pharmacology
2011 - 2011
R&D Transfection
2009 - 2009